Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCheckit Regulatory News (CKT)

Share Price Information for Checkit (CKT)

Share Price is delayed by 15 minutes
Get Live Data
21.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 1.00 (4.762%)
Market Cap: £23.22m
CKT Live PriceLast checked at - London Stock Exchange

Intraday Checkit Share Chart

Trading Update

10 Nov 2020 07:00

RNS Number : 7364E
Checkit PLC
10 November 2020
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014. UPON THE PUBLICATION OF THIS ANNOUNCEMENT THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE WITHIN THE PUBLIC DOMAIN.

10 November 2020

 

Checkit plc

("Checkit" or the "the Group")

 

Trading update

 

The Group provides a trading update for the nine months to 31 October 2020. A summary of the Group's unaudited Revenue for the three months to October 2020 ("Q3 FY21") and year to date is as follows:

 

REVENUES (UNAUDITED) (£m)

Three months to

Nine months to

 

 

 

31 Oct

2020 Actual

31 Oct

2019

Actual

Change

%

31 Oct

2020 Actual

31 Oct 2019

Actual

31 Oct 2019

Normalised*

Change Normalised*

%

Checkit Connect:

Recurring

1.3

1.0

+30%

3.6

2.2

2.9

+24%

Non-recurring

0.3

0.5

(40) %

1.4

1.0

1.5

(7) %

Total Checkit Connect

1.6

1.5

+7%

5.0

3.2

4.4

+14%

Total Checkit BEMS

1.8

1.9

(5) %

4.8

3.4

5.2

(8) %

  (Non - recurring)

Total Group

3.4

3.4

0%

9.8

6.6

9.6

+2%

 

* Normalised sales illustrate sales that would have been included in the Group's financial results had Checkit UK Limited, which was acquired on 14 May 2019, been owned by the Group throughout both periods.

 

The business performed ahead of the Board's expectations during Q3 FY21.

 

The period saw an improvement in the Checkit BEMS revenue run rate compared to Q2, as government restrictions eased and field engineers returned to customer sites for installation projects. A first half slowdown in sales of lower margin installation business (due to COVID-19) resulted in a 5% decline in the Checkit BEMs revenue line compared to the prior period.

 

Checkit Connect Recurring revenues for Q3 FY21 grew 30% compared to the prior period, continuing the trend reported in the Group's interim results. During the period there were further conversions of existing annual calibration and maintenance contracts into subscription-based income.

 

Cash

Cash at 31 October 2020 was £12.4m (31 January 2020: £14.3m; 31 July 2020: £13.4m).

 

Outlook

The Board continues to monitor the situation in view of the current uncertainties but remains confident in the medium and long term opportunities for the business.

 

Forward looking statements

This document contains forward looking statements with respect to the business, strategy and plans of Checkit plc and its current goals and expectations relating to its future financial condition and performance. Statements that are not historical facts, including statements about Checkit or management's beliefs and expectations, are forward looking statements. By their nature, forward looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Checkit's actual future results may differ materially from the results expressed or implied in these forward looking statements as a result of a variety of factors among other things, the economic and business circumstances occurring from time to time in the countries, sectors and business segments in which the Group operates. The forward looking statements contained in this document are made as of the date hereof, and Checkit undertakes no obligation to update any of its forward looking statements

 

 Checkit plc +44 (0) 1223 371000

 www.checkit.net

 Keith Daley (Executive Chair)

 Aylsa Muir (Chief Financial Officer)

 

 

 N+1 Singer (Nominated Adviser & Broker) +44 (0) 20 7496 3000

 Shaun Dobson / George Tzimas (Corporate Finance)

 Rachel Hayes (Corporate Broking)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBRBDBCDGDGGC
Date   Source Headline
1st Aug 20167:00 amRNSDirector/PDMR Shareholding
28th Jul 20163:56 pmRNSResult of AGM
28th Jul 20167:00 amRNSTrading Update
4th Jul 201610:40 amRNSLapsing of Options
30th Jun 20167:00 amRNSAnnual Report and Notice of AGM
9th Jun 20167:00 amRNSFinal Results
23rd May 20167:00 amRNSDisposal of Agar Scientific
18th May 20169:56 amRNSHolding(s) in Company
13th May 201610:06 amRNSHolding(s) in Company
20th Apr 20162:54 pmRNSDerivative Claim - Update
22nd Feb 20167:00 amRNSTrading Update
26th Jan 20167:00 amRNSDirectorate Change
20th Jan 20163:22 pmRNSHolding(s) in Company
25th Nov 20157:00 amRNSProduct Launch
24th Nov 20153:21 pmRNSHolding(s) in Company
10th Nov 20157:00 amRNSTrading Update
19th Oct 20153:41 pmRNSDerivative Claim - Update
5th Oct 20157:00 amRNSProduct Launch
28th Sep 20157:00 amRNSDirector's Dealing
14th Sep 20154:12 pmRNSDirector's dealing
10th Sep 20157:00 amRNSDirectorate Changes
10th Sep 20157:00 amRNSHalf Yearly Report
30th Jul 20154:45 pmRNSResult of AGM
23rd Jul 20159:00 amRNSTrading Update
22nd Jul 20157:00 amRNSDerivative claim - update
16th Jul 20154:09 pmRNSDerivative Claim - Update
8th Jul 20153:16 pmRNSLapse of Options
6th Jul 20153:49 pmRNSNotice of AGM
26th Jun 20154:00 pmRNSHolding(s) in Company
18th Jun 20158:50 amRNSDerivative Claim - Update
12th Jun 20154:42 pmRNSAnnual Report and Financial Statements
30th Apr 20157:00 amRNSFinal Results
27th Apr 20155:35 pmRNSHolding(s) in Company
7th Apr 20151:41 pmRNSHolding(s) in Company
12th Feb 20157:00 amRNSYear end trading update
28th Jan 201512:45 pmRNSDerivative Claim - Further Update
24th Nov 20147:00 amRNSTrading update
2nd Oct 20147:00 amRNSDerivative Claim - Update
31st Jul 20146:06 pmRNSResult of AGM
31st Jul 20147:00 amRNSAGM Statement
25th Jul 201411:15 amRNSDirector/PDMR Shareholding
17th Jul 201412:15 pmRNSResult of Open Offer
9th Jul 20148:00 amRNSNotice of AGM
25th Jun 20145:42 pmRNSHolding(s) in Company
23rd Jun 20147:00 amRNSPlacing and Proposed Open Offer
23rd Jun 20147:00 amRNSUnaudited full year results
20th Jun 20147:00 amRNSConclusion of Strategic Alternatives Process
17th Jun 20147:00 amRNSStatement regarding Elektron Technology plc
2nd Jun 20145:33 pmRNSForm 8 (OPD) Microgen plc
2nd Jun 201412:35 pmRNSForm 8.3 - [Microgen Plc]

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.